WAY-362692 is a secreted frizzled-related protein ( sFRP-1 ) inhibitor ( IC50 of 0.02 μM), targeting the netrin domain of sFRP-1. WAY-362692 can competitively inhibit the interaction between sFRP-1 and Wnt proteins, and activate the Wnt/β-catenin signaling pathway ( EC 50 = 0.03 μM). WAY-362692 can activate osteoblasts and promote bone remodeling. WAY-362692 can be used for the research of metabolic disease, such as osteoporosis [1].
In Vitro, WAY-362692 (Compound 7b) (0.1-1 nM, 7 days) induces osteoblast activation and bone remodeling and increases the total bone area of 4-day-old neonatal mouse calvariae[1].
References:
[1]. Moore WJ, et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem. 2009 Jan 8;52(1):105-16.
In Vitro, WAY-362692 (Compound 7b) (0.1-1 nM, 7 days) induces osteoblast activation and bone remodeling and increases the total bone area of 4-day-old neonatal mouse calvariae[1].
References:
[1]. Moore WJ, et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem. 2009 Jan 8;52(1):105-16.